Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Mar;19(1):108-11.
doi: 10.4103/0972-2327.175435.

Limb-girdle muscular dystrophy in the Agarwals: Utility of founder mutations in CAPN3 gene

Affiliations

Limb-girdle muscular dystrophy in the Agarwals: Utility of founder mutations in CAPN3 gene

Satish V Khadilkar et al. Ann Indian Acad Neurol. 2016 Jan-Mar.

Abstract

Background and purpose: Diagnostic evaluation of limb-girdle muscular dystrophy type 2A (LGMD2A) involves specialized studies on muscle biopsy and mutation analysis. Mutation screening is the gold standard for diagnosis but is difficult as the gene is large and multiple mutations are known. This study evaluates the utility of two known founder mutations as a first-line diagnostic test for LGMD2A in the Agarwals.

Materials and methods: The Agarwals with limb-girdle muscular dystrophy (LGMD) phenotype were analyzed for two founder alleles (intron 18/exon 19 c.2051-1G>T and exon 22 c.2338G>C). Asymptomatic first-degree relatives of patients with genetically confirmed mutations and desirous of counseling were screened for founder mutations.

Results: Founder alleles were detected in 26 out of 29 subjects with LGMD phenotype (89%). The most common genotype observed was homozygous for exon 22 c.2338 G>C mutation followed by compound heterozygosity. Single founder allele was identified in two. Single allele was detected in two of the five asymptomatic relatives.

Conclusion: Eighty-nine percent of the Agarwals having LGMD phenotype have LGMD2A resulting from founder mutations. Founder allele analysis can be utilized as the initial noninvasive diagnostic step for index cases, carrier detection, and counseling.

Keywords: Agarwal; calpainopathy; founder mutation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Sangers sequencing showing CAPN3-Ex 22 homozygous mutation c.2338 G>C in patient sample (arrow) (b) Sangers sequencing showing CAPN3-Intron 18/Ex 19 heterozygous mutation c.2051-1G>T in patient sample (arrow)
Figure 2
Figure 2
(a) Showing scapular winging (b) Showing toe walking due to ankle contractures

Similar articles

Cited by

References

    1. Angelini C, Fanin M. Calpainopathy. 2005 May 10. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews® [Internet] Seattle (WA): University of Washington, Seattle; 1993-2015; [Last accessed on 2014 Nov 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1313/
    1. Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, et al. Molecular diagnosis in LGMD2A: Mutation analysis or protein testing? Hum Mutat. 2004;24:52–62. - PubMed
    1. Bushby KM. Making sense of the limb-girdle muscular dystrophies. Brain. 1999;122:1403–20. - PubMed
    1. Urtizberea JA, Leturcq F. Limb girdle muscular dystrophies: The clinicopathological viewpoint. Ann Indian Acad Neurol. 2007;10:214–24.
    1. Fanin M, Angelini C. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2a: The yield and the pitfalls. Muscle Nerve. 2015;52:163–73. - PubMed